TTrialPathMatch Me to Trials
← Back to trials
RecruitingCADASIL

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study

Eligible age

18+ yrs

Accepts

All genders

Locations

10 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is an observational study to better understand the risk factors and progression of CADASIL, a leading cause of vascular cognitive impairment and dementia (VCID). 575 participants will be enrolled and can expect to be on study for up to 5 years.

Sponsor: University of Wisconsin, Madison

You may qualify if…

  • ✓ 1. Must be at least 18 years old
  • ✓ 2. Positive NOTCH3 genetic testing; OR a positive skin biopsy; OR a willingness to have a NOTCH3 genetic test completed prior to enrolling AND are at-risk for, or diagnosed clinically with, CADASIL
  • ✓ 3. Willing to commit to three in-person visits (a baseline visit, an 18-month follow-up, and a 36-month follow-up) and to remote visits as needed by phone, email, mail or internet
  • ✓ 4. Willing to provide documentation of all current medications to study team
  • ✓ a. All medications will be allowed throughout the course of study. Documentation of medications will be used for analyses to assess potential impact of medications on study outcomes.
  • ✓ 5. Willing and able to undergo an MRI scan and blood draw at each in-person visit
  • ✓ 6. Must have a designated "study companion"
  • ✓ a. A "study companion" is someone who knows the participant well (has greater than or equal to 3 hours/month of contact with the CADASIL participant) and can provide additional information to the study team (either remotely or in-person).

You may not qualify if…

  • ✕ 1. History of severe learning disability, intellectual disability, or other neurological disease or event not attributable to CADASIL
  • ✕ 2. History of serious alcohol or drug abuse within the past year
  • ✕ 3. Unwilling to undergo NOTCH3 genetic testing if there is no test on file

Where it's recruiting

California

Los Angeles · San Francisco

Colorado

Denver

Georgia

Atlanta

Illinois

Chicago

New York

New York

Oregon

Portland

Rhode Island

Providence

Texas

Houston · San Antonio

Utah

Salt Lake City

Washington

Seattle

Source: ClinicalTrials.gov · NCT05677880 · last updated 2026-01-15

Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and · TrialPath